This is exactly why I feel IPIX success expectations for each successive trial test should be far greater than the norm. Kevetrin phase 1 had to be stopped because they couldn't reach a termination safety issue prior to dosage level not further improving chances of condition termination success, Prurisol comes from an FDA approved drug with an outstanding safety history, and Brilacidin not showing any adverse effects of note in any of its many different trials.

I understand the need for being conservative, but those giving the chance of success for Prurisol P2b as barely above 50-60% makes me scratch my head.